Tenax Therapeutics Management

Management criteria checks 4/4

We currently do not have sufficient information about the CEO.

Key information

Chris Giordano

Chief executive officer

US$644.8k

Total compensation

CEO salary percentage	62.9%
CEO tenure	2.8yrs
CEO ownership	n/a
Management average tenure	2.8yrs
Board average tenure	3.3yrs

Recent management updates

Recent updates

Tenax to evaluate strategic alternatives including a sale or a merger, shares rise ~7%

Sep 15

Are Insiders Selling Tenax Therapeutics, Inc. (NASDAQ:TENX) Stock?

Jan 20

CEO Compensation Analysis

How has Chris Giordano's remuneration changed compared to Tenax Therapeutics's earnings?
Date	Total Compensation	Salary	Company Earnings
Dec 31 2023	US$645k	US$405k	-US$8m
Sep 30 2023	n/a	n/a	-US$7m
Jun 30 2023	n/a	n/a	-US$8m
Mar 31 2023	n/a	n/a	-US$10m
Dec 31 2022	US$667k	US$386k	-US$11m
Sep 30 2022	n/a	n/a	-US$12m
Jun 30 2022	n/a	n/a	-US$13m
Mar 31 2022	n/a	n/a	-US$11m
Dec 31 2021	US$861k	US$183k	-US$32m

Compensation vs Market: Chris's total compensation ($USD644.77K) is about average for companies of similar size in the US market ($USD667.63K).

Compensation vs Earnings: Chris's compensation has been consistent with company performance over the past year.

CEO

Chris Giordano (48 yo)

2.8yrs

Tenure

US$644,770

Compensation

Mr. Christopher T. Giordano, also known as Chris, has been the Chief Executive Officer and Director of Tenax Therapeutics, Inc. since joining on July 14, 2021 and serves as its President since October 29,...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Christopher Giordano	CEO, President & Director	2.8yrs	US$644.77k	no data
Stuart Rich	Chief Medical Officer & Director	3.3yrs	US$481.22k	0.14% $ 10.4k
Lawrence Hoffman	Interim Chief Financial Officer	less than a year	no data	no data
Doug Randall	Executive Vice President of Commercial & Business Operations	no data	no data	no data
Douglas Hay	Senior Vice President of Regulatory Affairs	no data	no data	no data

2.8yrs

Average Tenure

68yo

Average Age

Experienced Management: TENX's management team is considered experienced (2.8 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
Christopher Giordano	CEO, President & Director	2.8yrs	US$644.77k	no data
Stuart Rich	Chief Medical Officer & Director	3.3yrs	US$481.22k	0.14% $ 10.4k
Gerald Proehl	Independent Chairman	10.1yrs	US$81.11k	0.000050% $ 3.8
Michael Davidson	Independent Director	3.3yrs	US$60.11k	0.019% $ 1.5k
Daniel Burkhoff	Member of PH-Left Heart Disease Scientific Advisory Board	6.3yrs	no data	no data
Declan Doogan	Independent Director	3.3yrs	US$51.11k	0.12% $ 8.9k
Robyn Hunter	Independent Director	2.3yrs	US$68.26k	0% $ 0
June Almenoff	Independent Director	3.3yrs	US$62.11k	0% $ 0
Sanjiv Shah	Member of PH-Left Heart Disease Scientific Advisory Board	6.3yrs	no data	no data
Barry Borlaug	Member of PH-Left Heart Disease Scientific Advisory Board	4.3yrs	no data	no data
Robert Frantz	Member of PAH Scientific Advisory Board	no data	no data	no data
Anna Hemnes	Member of PAH Scientific Advisory Board	no data	no data	no data

3.3yrs

Average Tenure

66yo

Average Age

Experienced Board: TENX's board of directors are considered experienced (3.3 years average tenure).

Tenax Therapeutics Management

Management criteria checks 4/4

Key information

Recent management updates

Tenax Therapeutics, Inc., Annual General Meeting, Jun 07, 2024

Tenax Therapeutics, Inc. Appoints Lawrence R. Hoffman as Principal Financial Officer and Principal Accounting Officer

Tenax Therapeutics, Inc. Appoints Javed Butler to its PH-HFpEF Scientific Advisory Board

High number of new and inexperienced directors

Tenax Therapeutics, Inc. Announces Resignation of Executives

High number of new and inexperienced directors

Recent updates

Tenax Therapeutics, Inc., Annual General Meeting, Jun 07, 2024

New minor risk - Profitability

Tenax Therapeutics Enrolls First Patient in Phase 3 Level Study Evaluating TNX-103 (Oral Levosimendan) for the Treatment of Pulmonary Hypertension in PH-HFpEF Patients

Tenax Therapeutics, Inc. Appoints Lawrence R. Hoffman as Principal Financial Officer and Principal Accounting Officer

Tenax Therapeutics Receives Non-Compliance Notice from Nasdaq

Forecast to breakeven in 2026

Tenax Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $36 million.

Tenax Therapeutics, Inc. Appoints Javed Butler to its PH-HFpEF Scientific Advisory Board

Tenax Therapeutics, Inc. Announces FDA Clearance of IND for TNX-103 for the Treatment of Pulmonary Hypertension with Heart Failure

New major risk - Share price stability

The Nasdaq Stock Market LLC Grants Tenax Therapeutics's Request for an Extension Through March 25, 2024 to Evidence Compliance with the $1.00 Per Share Requirement for Continued Inclusion on the Nasdaq Capital Market

Tenax Therapeutics Issues U.S. Patent for Oral Levosimendan in Pulmonary Hypertension with Heart Failure with Preserved Ejection Fraction (PH-HFpEF)

Tenax Therapeutics, Inc. Receives a Notice of Allowance from the United States Patent and Trademark Office for its Patent Application

Price target increased by 16% to US$110

Tenax Receives Notice of Allowance for U.S. Patent Application Covering Use of IV Levosimendan in Pulmonary Hypertension with Heart Failure and Preserved Ejection Fraction (PH-HFpEF)

High number of new and inexperienced directors

Tenax Therapeutics, Inc. Announces the Presentation of Positive Data from a Study of PH-HFpEF Patients Being Treated with Oral Levosimendan

Tenax to evaluate strategic alternatives including a sale or a merger, shares rise ~7%

Tenax Therapeutics, Inc. Receives Formal Notice That the Nasdaq Stock Market LLC

Forecast to breakeven in 2023

Tenax Therapeutics, Inc. Announces Resignation of Executives

Price target decreased to US$4.00

Tenax Therapeutics, Inc. Announces Successful Comparative Pharmacokinetic Study of TNX-201 for the Treatment of Pulmonary Arterial Hypertension

Tenax Therapeutics, Inc. announced that it expects to receive $8 million in funding from Armistice Capital LLC

High number of new and inexperienced directors

Tenax Therapeutics, Inc. Appoints Robyn Hunter to the Board of Directors

Tenax Therapeutics Provides Update on TNX-102, TNX-103 and TNX-201 Clinical Programs

High number of new and inexperienced directors

Forecast to breakeven in 2022

Price target increased to US$4.75

Independent Director James Mitchum has left the company

Tenax Therapeutics, Inc. Announces New Publication Highlighting Novel Levosimendan Mechanism of Action in Pulmonary Hypertension Patients with Heart Failure and Preserved Ejection Fraction

High number of new directors

CEO & Director Anthony DiTonno has left the company

Independent Director Chris Rallis has left the company

Independent Director Gregory Pepin has left the company

Independent Chairman Ronald Blanck has left the company

Price target increased to US$4.75

Tenax Therapeutics, Inc. Expands Board of Directors

New 90-day high: US$2.78

Tenax Therapeutics, Inc. (NasdaqCM:TENX) acquired PH Precision Med Inc. for $21.6 million.

Are Insiders Selling Tenax Therapeutics, Inc. (NASDAQ:TENX) Stock?

New 90-day high: US$2.36

New 90-day high: US$1.98

Tenax Therapeutics, Inc. Announces Presentation of 24-Hour HELP Study Results at the American Heart Association Scientific Sessions 2020

New 90-day low: US$1.18

Tenax Therapeutics, Inc. Enters into Amendment to License Agreement with Orion Corporation

Tenax Therapeutics Announces Late-Breaking Clinical Trial Presentation of Phase 2 HELP Study at Heart Failure Society of America (HFSA) Virtual Annual Scientific Meeting

New 90-day high: US$1.63

Price target lowered to US$4.23

Tenax Therapeutics, Inc. announced that it has received $4.735325 million in funding

Tenax Therapeutics, Inc. announced that it expects to receive $4.735325 million in funding

CEO Compensation Analysis

CEO

Tenure

Compensation

Leadership Team

Average Tenure

Average Age

Board Members

Average Tenure

Average Age